SARS-CoV-2, like all RNA viruses, evolves and mutates. Since its discovery, the viral sequence for the novel coronavirus has accumulated a staggering number of mutations, giving rise to more virulent, transmissible and deadly variations that are taking hold across the globe. Since the virus can evolve, the assays designed to detect it must evolve as well.
The Fluidigm RT-PCR based Advanta® SARS-CoV-2 Mutation Assay Panel is an expansion of the Advanta pathogen detection portfolio and can concurrently detect the reference virus and mutations associated with six Variants of Concern identified by the CDC and WHO. Leveraging our proprietary microfluidics technology along with the Biomark™ HD platform and an IFC controller, the detection of these new mutations is performed seamlessly without the need for additional integrated fluidic circuits (IFCs), run reagents or sample volume, providing more data without additional labor. As the virus continues to evolve, the assay’s open design enables this solution to evolve along with it.
- Reflex-free workflow: Detects SARS-CoV-2 and key mutations concurrently from the same input sample on one IFC, saving reagents, samples and time
- Saliva-based and extraction-free: Performs equivalently to comparator nasal tests utilizing convenient and noninvasive sample collection without the need for commercial extraction kits
- More valuable data: Supports detection and surveillance of key mutations from a single high-throughput workflow that supports up to 6,000 samples per day
- Flexible: Enables convenient addition of mutations emerging in the future, unlike other multiplex RT-PCR assays, due to the open architecture of the IFC
|L452R mutant||K417N mutant||N501Y mutant|
|L452R wild type||K417N wild type||N501Y wild type|
|∆69/70 mutant||K417T mutant||E484K mutant|
|∆69/70 wild type||K417T wild type||E484K wild type|